Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions
Loading...
Date
2019-08
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Wolters Kluwer India Pvt. Ltd.
Abstract
The development of inhibitors of immune checkpoints has revolutionized the treatment for a subset of patients with advanced nonsmall cell lung cancer (NSCLC), resulting in promising clinical outcomes and durable responses. Pembrolizumab, a humanized anti-programmed cell death-1 (PD-1) antibody, has been approved as a first-line treatment for patients with advanced NSCLC with PD-L1 expression of ≥50% and as a second-line treatment for PD-L1 expression of ≥1%. Pembrolizumab in combination with standard chemotherapy has shown better clinical outcomes than chemotherapy as a first-line therapy in patients with advanced NSCLC without targetable mutations, regardless of PD-L1 expression. In this review, we summarized the current indications of pembrolizumab for NSCLC, briefly described immune-relevant pneumonitis and discussed potential biomarkers to predict clinical efficacy.
Description
Keywords
Citation
Qin Qin, Li Baosheng. Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions. Journal of Cancer Research and Therapeutics. 2019 Aug; 15(4): 743-750